Malta - English - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 milligram(s)/millilitre - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 milligram(s)/millilitre - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 2 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group hf - epirubicin hydrochloride - solution for injection - 2 milligram(s)/millilitre - anthracyclines and related substances; epirubicin

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - epirubicin hydrochloride - solution for inj/inf - 2 micromol - anthracyclines and related substances

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride ? the active substance in farmorubicin ? belongs to a group of active substances known as anthracyclines. these cell-damaging active substances are used to treat cancer. epirubicin is used alone or in combination with other medicines for the treatment of the following types of cancer: ? breast cancer ? stomach cancer ? lung cancer ? ovarian cancer ? prostate cancer ? colon cancer ? soft tissue sarcomas (malignant tumours of the soft tissue such as fatty tissue, muscle tissue or connective tissue) epirubicin is also used intravesically (i.e. administration into the bladder) to treat early (superficial) cancer of the bladder or to prevent the recurrence of bladder cancer following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride is indicated for the treatment of a group of neoplastic conditions including: for intravenous administration: - breast cancer - gastro-esophageal cancer - small-cell lung cancer - advanced ovarian cancer - soft-tissue and bone sarcomas when administered intravesically, epirubicin has been shown to be beneficial in the treatment of: - papillary transitional cell bladder cancer - carcinoma-in-situ of the bladder - intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride is indicated for the treatment of a group of neoplastic conditions including: for intravenous administration: - breast cancer - gastro-esophageal cancer - small-cell lung cancer - advanced ovarian cancer - soft-tissue and bone sarcomas when administered intravesically, epirubicin has been shown to be beneficial in the treatment of: - papillary transitional cell bladder cancer - carcinoma-in-situ of the bladder - intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection.